Who are Bazedoxifene/Conjugated Estrogen's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bazedoxifene-conjugated-estrogen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bazedoxifene/Conjugated Estrogen — Competitive Intelligence Brief

Bazedoxifene/Conjugated Estrogen (Bazedoxifene/Conjugated Estrogen) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Estrogen Receptor Modulator (SERM) combined with Conjugated Estrogens. Area: Women's Health / Endocrinology.

marketed Selective Estrogen Receptor Modulator (SERM) combined with Conjugated Estrogens Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Women's Health / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Bazedoxifene/Conjugated Estrogen (Bazedoxifene/Conjugated Estrogen) — University of North Carolina, Chapel Hill. Bazedoxifene acts as a selective estrogen receptor modulator (SERM) that provides estrogen-like benefits while blocking estrogen effects in breast tissue, combined with conjugated estrogens for menopausal symptom relief.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bazedoxifene/Conjugated Estrogen TARGET	Bazedoxifene/Conjugated Estrogen	University of North Carolina, Chapel Hill	marketed	Selective Estrogen Receptor Modulator (SERM) combined with Conjugated Estrogens	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Estrogen Receptor Modulator (SERM) combined with Conjugated Estrogens class)

University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bazedoxifene/Conjugated Estrogen — Competitive Intelligence Brief. https://druglandscape.com/ci/bazedoxifene-conjugated-estrogen. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab